Intravenous Statin Administration During Myocardial Infarction Compared With Oral Post-Infarct Administration.

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Regenerative Medicine

Background:

• Statins offer cardioprotective benefits beyond lipid-lowering.
• High-dose statin therapy may decrease cardiovascular complications in high-risk individuals.
• Optimal timing and administration of statins for cardioprotection remain undetermined.

Purpose of the Study:

• To compare the cardioprotective effects of intravenous atorvastatin administered during myocardial infarction (MI) versus oral administration immediately post-MI.

Main Methods:

• Hypercholesterolemic pigs underwent induced MI (90 minutes ischemia) and were monitored for 42 days.
• Three groups were studied: intravenous atorvastatin during MI (A1), intravenous vehicle during MI (A2), and oral atorvastatin post-MI (A3).
• Cardiac MRI, molecular, and histological analyses were performed at 3 and 42 days post-MI.

Main Results:

• Intravenous atorvastatin (A1) reduced infarct size by 10% and increased myocardial salvage by 50% at day 3 compared to A3 and A2.
• At day 42, both A1 and A3 reduced scar size versus A2, with A1 showing an additional 24% reduction versus A3.
• A1 demonstrated improved systolic function, reduced wall motion abnormalities, enhanced collagen content, increased vessel density, and modulated inflammatory markers.

Conclusions:

• Intravenous atorvastatin during MI offers superior cardioprotection, limiting cardiac damage and improving function more effectively than oral administration post-MI.
• This intravenous administration strategy warrants further investigation in patients with ST-segment elevation myocardial infarction.
• The findings suggest a potential new therapeutic window for statin administration in acute cardiac events.